Spinal interleukin-33 and its receptor ST2 contribute to bone cancer-induced pain in mice

Neuroscience

Volumn 253, Issue , 2013, Pages 172-182

  Zhao, J ^a   Zhang, H ^a   Liu, S B ^a   Han, P ^a   Hu, S ^a   Li, Q ^a   Wang, Z F ^a   Mao Ying, Q L ^a   Chen, H M ^b   Jiang, J W ^a   Wu, G C ^a   Mi, W L ^a   Wang, Y Q ^a  

^a FUDAN UNIVERSITY   (China)

^b ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Bone cancer induced pain; Interleukin 33; Proinflammatory cytokines; Spinal cord; ST2

Indexed keywords

IMMUNOGLOBULIN G; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; MESSENGER RNA; NEUTRALIZING ANTIBODY; ONCOPROTEIN; PROTEIN ST2; PROTEIN ST2 NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CANCER; BONE DESTRUCTION; BREAST CARCINOMA; CANCER PAIN; CONTROLLED STUDY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE COMPARISON; FEMALE; GENE INACTIVATION; HISTOPATHOLOGY; HYPERALGESIA; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ST2 GENE; TUMOR INVASION; UPREGULATION;

BONE CANCER-INDUCED PAIN; ERK; EXTRACELLULAR SIGNAL-REGULATED KINASE; GFAP; GLIAL FIBRILLARY ACIDIC PROTEIN; HORSERADISH PEROXIDASE; HRP; IL; INTERLEUKIN; INTERLEUKIN-33; P-P38MAPK; PAW WITHDRAWAL MECHANICAL THRESHOLD; PAW WITHDRAWAL THERMAL LATENCY; PBS; PHOSPHATE-BUFFERED SALINE; PHOSPHORYLATED-P38MAPK; PROINFLAMMATORY CYTOKINES; PWL; PWT; SPINAL CORD; ST2; T HELPER; TH; WILD-TYPE; WT;

ANIMALS; BONE AND BONES; BONE NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HYPERALGESIA; IMMUNOGLOBULIN G; INTERLEUKINS; LOCOMOTION; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PAIN; PAIN MEASUREMENT; RECEPTORS, INTERLEUKIN; SPINAL CORD; TIME FACTORS;

EID: 84884724724     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.08.026     Document Type: Article

References (43)

1. Ali S., Mohs A., Thomas M., Klare J., Ross R., Schmitz M.L., Martin M.U. The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol 2011, 187:1609-1616.
2. Arend W.P., Palmer G., Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008, 223:20-38.
3. Baekkevold E.S., Roussigne M., Yamanaka T., Johansen F.E., Jahnsen F.L., Amalric F., Brandtzaeg P., Erard M., Haraldsen G., Girard J.P. Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol 2003, 163:69-79.
4. Banning A., Sjogren P., Henriksen H. Treatment outcome in a multidisciplinary cancer pain clinic. Pain 1991, 47(129-134):127-128.
5. Brint E.K., Xu D., Liu H., Dunne A., McKenzie A.N., O'Neill L.A., Liew F.Y. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat Immunol 2004, 5:373-379.
6. Cayrol C., Girard J.P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 2009, 106:9021-9026.
7. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12:6243s-6249s.
8. Dixon W.J. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980, 20:441-462.
9. Dyer K.D., Percopo C.M., Rosenberg H.F. IL-33 promotes eosinophilia in vivo and antagonizes IL-5-dependent eosinophil hematopoiesis ex vivo. Immunol Lett 2012, 150:41-47.
10. Han P., Zhao J., Liu S.B., Yang C.J., Wang Y.Q., Wu G.C., Xu D.M., Mi W.L. Interleukin-33 mediates formalin-induced inflammatory pain in mice. Neuroscience 2013, 241:59-66.
11. Hansen R.R., Nielsen C.K., Nasser A., Thomsen S.I., Eghorn L.F., Pham Y., Schulenburg C., Syberg S., Ding M., Stojilkovic S.S., Jorgensen N.R., Heegaard A.M. P2X7 receptor-deficient mice are susceptible to bone cancer pain. Pain 2011, 152:1766-1776.
12. Honore P., Rogers S.D., Schwei M.J., Salak-Johnson J.L., Luger N.M., Sabino M.C., Clohisy D.R., Mantyh P.W. Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience 2000, 98:585-598.
13. Hudson C.A., Christophi G.P., Gruber R.C., Wilmore J.R., Lawrence D.A., Massa P.T. Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol 2008, 84:631-643.
14. Hylden J.L., Wilcox G.L. Intrathecal morphine in mice: a new technique. Eur J Pharmacol 1980, 67:313-316.
15. Jiang H.R., Milovanovic M., Allan D., Niedbala W., Besnard A.G., Fukada S.Y., Alves-Filho J.C., Togbe D., Goodyear C.S., Linington C., Xu D., Lukic M.L., Liew F.Y. IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages. Eur J Immunol 2012, 42:1804-1814.
16. Jimenez-Andrade J.M., Mantyh W.G., Bloom A.P., Ferng A.S., Geffre C.P., Mantyh P.W. Bone cancer pain. Ann N Y Acad Sci 2010, 1198:173-181.
17. Liew F.Y. IL-33: a Janus cytokine. Ann Rheum Dis 2012, 71(Suppl 2):i101-i104.
18. Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010, 10:103-110.
19. Mantyh P.W., Hunt S.P. Mechanisms that generate and maintain bone cancer pain. Novartis Found Symp 2004, 260:221-238. 238-240, 277-279.
20. Mantyh P.W., Clohisy D.R., Koltzenburg M., Hunt S.P. Molecular mechanisms of cancer pain. Nat Rev Cancer 2002, 2:201-209.
21. Mao-Ying Q.L., Wang X.W., Yang C.J., Li X., Mi W.L., Wu G.C., Wang Y.Q. Robust spinal neuroinflammation mediates mechanical allodynia in Walker 256 induced bone cancer rats. Mol Brain. 2012, 5:16.
22. Mao-Ying Q.L., Zhao J., Dong Z.Q., Wang J., Yu J., Yan M.F., Zhang Y.Q., Wu G.C., Wang Y.Q. A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cells. Biochem Biophys Res Commun 2006, 345:1292-1298.
23. Menendez L., Juarez L., Garcia E., Garcia-Suarez O., Hidalgo A., Baamonde A. Analgesic effects of capsazepine and resiniferatoxin on bone cancer pain in mice. Neurosci Lett 2006, 393:70-73.
24. Miller A.M. Role of IL-33 in inflammation and disease. J Inflamm (Lond) 2011, 8:22.
25. Minami K., Hasegawa M., Ito H., Nakamura A., Tomii T., Matsumoto M., Orita S., Matsushima S., Miyoshi T., Masuno K., Torii M., Koike K., Shimada S., Kanemasa T., Kihara T., Narita M., Suzuki T., Kato A. Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models. J Pharmacol Sci 2009, 111:60-72.
26. Nakanishi M., Hata K., Yoneda T. Encounter of cancer cells with bone. Molecular mechanism of cancer-induced bone pain. Clin Calcium 2011, 21:357-363.
27. Ohto-Ozaki H., Kuroiwa K., Mato N., Matsuyama Y., Hayakawa M., Tamemoto H., Tominaga S. Characterization of ST2 transgenic mice with resistance to IL-33. Eur J Immunol 2010, 40:2632-2642.
28. Pacharinsak C., Beitz A. Animal models of cancer pain. Comp Med 2008, 58:220-233.
29. Prefontaine D., Lajoie-Kadoch S., Foley S., Audusseau S., Olivenstein R., Halayko A.J., Lemiere C., Martin J.G., Hamid Q. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009, 183:5094-5103.
30. Ren B.X., Gu X.P., Zheng Y.G., Liu C.L., Wang D., Sun Y.E., Ma Z.L. Intrathecal injection of metabotropic glutamate receptor subtype 3 and 5 agonist/antagonist attenuates bone cancer pain by inhibition of spinal astrocyte activation in a mouse model. Anesthesiology 2012, 116:122-132.
31. Schmitz J., Owyang A., Oldham E., Song Y., Murphy E., McClanahan T.K., Zurawski G., Moshrefi M., Qin J., Li X., Gorman D.M., Bazan J.F., Kastelein R.A. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 2005, 23:479-490.
32. Schwei M.J., Honore P., Rogers S.D., Salak-Johnson J.L., Finke M.P., Ramnaraine M.L., Clohisy D.R., Mantyh P.W. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999, 19:10886-10897.
33. Smith D.E. The biological paths of IL-1 family members IL-18 and IL-33. J Leukoc Biol 2011, 89:383-392.
34. Smith H.S. Painful osseous metastases. Pain Physician 2011, 14:E373-E403.
35. Takahashi S. Clinical characteristics of bone metastases of breast cancer. Nihon Rinsho 2012, 70(Suppl 7):118-123.
36. Verri W.J., Guerrero A.T., Fukada S.Y., Valerio D.A., Cunha T.M., Xu D., Ferreira S.H., Liew F.Y., Cunha F.Q. IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice. Proc Natl Acad Sci U S A 2008, 105:2723-2728.
37. Wakabayashi H., Hiraga T., Yoneda T. Mechanism of bone cancer pain. Clin Calcium 2006, 16:605-611.
38. Wang X.W., Li T.T., Zhao J., Mao-Ying Q.L., Zhang H., Hu S., Li Q., Mi W.L., Wu G.C., Zhang Y.Q., Wang Y.Q. Extracellular signal-regulated kinase activation in spinal astrocytes and microglia contributes to bone cancer pain in rats. Neuroscience 2012, 217:172-181.
39. Yasuoka S., Kawanokuchi J., Parajuli B., Jin S., Doi Y., Noda M., Sonobe Y., Takeuchi H., Mizuno T., Suzumura A. Production and functions of IL-33 in the central nervous system. Brain Res 2011, 1385:8-17.
40. Zhang R., Lao L. A new rat model of bone cancer pain. Methods Mol Biol 2012, 851:261-273.
41. Zhang R.X., Liu B., Li A., Wang L., Ren K., Qiao J.T., Berman B.M., Lao L. Interleukin 1beta facilitates bone cancer pain in rats by enhancing NMDA receptor NR-1 subunit phosphorylation. Neuroscience 2008, 154:1533-1538.
42. Zarpelon A., Cunha T., Alves-Filho J., Pinto L., Ferreira Sh., McInnes I., Xu D., Liew F., Cunha F., Verri W. Interleukin-33/ST2 signalling contributes to carrageenin-induced innate inflammation and inflammatory pain: role of cytokines, endothelin-1 and prostaglandin E(2). Br J Pharmacol 2013, 169(1):90-101.
43. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983, 16:109-110.